Recombinant HSV-1 Vector with IL-12 and PD-1 for Safer Oncolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic herpes simplex viruses (oHSV) face challenges with high toxicity, poor safety, and limited therapeutic doses due to low specificity and safety, affecting their clinical treatment efficacy and posing safety hazards.
Innovation Solution
A recombinant HSV-1 vector with a modified genome, featuring a deletion of the ICP34.5 gene and insertion of exogenous nucleic acid sequences encoding immunostimulatory factors like IL-12 and anti-immune checkpoint antibodies such as PD-1, specifically inserted between UL26 and UL27 genes, to enhance tumor suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oncolytic herpes simplex viruses are used for tumor treatment, then anti-tumor effects are achieved, but high toxicity and poor safety occur
Solution Approach 1:
The patent applies local quality by making the virus strain specific (HSV-1 KOS) and modifying it with specific deletions (ICP34.5 gene) and specific insertions (anti-tumor immunoregulation factors) to achieve targeted tumor killing while reducing non-specific toxicity to normal cells
Solution Approach 2:
The patent creates a composite viral construct by combining multiple elements: the HSV-1 KOS backbone, deletion of ICP34.5 gene for safety, and insertion of anti-tumor immunoregulation factors for enhanced efficacy, resulting in a multi-component therapeutic agent with improved safety profile
2Reliability
If dosage of oncolytic viruses is reduced to avoid side effects, then safety is improved, but therapeutic efficacy is compromised
Solution Approach 1:
The patent changes key parameters of the viral construct including gene deletions and insertions to fundamentally alter the virus's interaction with tumor cells, enabling effective anti-tumor activity at lower doses with reduced systemic toxicity
Solution Approach 2:
The patent converts the traditionally harmful ICP34.5 gene into a benefit by deleting it to reduce neurotoxicity, and by inserting anti-tumor immunoregulation factors that convert the virus's strong immunogenicity (which can cause side effects) into enhanced anti-tumor immune responses
3Productivity
If anti-tumor immunoregulation factors are assembled to enhance immune effect, then anti-tumor efficacy is improved, but device complexity increases
Solution Approach 1:
The patent merges multiple therapeutic functions into a single viral vector by co-expressing anti-tumor immunoregulation factors (such as IL-12, GM-CSF, or 4-1BB ligand) within the HSV-1 KOS genome, eliminating the need for multiple separate treatments
Solution Approach 2:
The patent creates a multi-functional viral vector that simultaneously provides: (1) direct oncolysis through viral replication, (2) immunostimulation through cytokine expression, and (3) immune checkpoint modulation, making it a universal platform applicable to various tumor types
Data Source
AI summary
The present disclosure provides a modified HSV-1 vector. The HSV-1 vector comprises an exogenous nucleotide sequence encoding an immunostimulatory factor and/or an anti-immune checkpoint antibody. The HSV-1 vector of the present disclosure can be used for treating cancers.